EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Microbiome-Mediated Pharmacokinetics and Informed Dosing of Mycophenolate in Kidney Transplantation

Abdelrahman Saqr, Moataz E Mohamed, Christopher Staley, Guillaume Onyeaghala, Duy Vo, Rory P Remmel, Levi Teigen, Weihua Guan, William S Oetting, Rasha El-Rifai, Casey R Dorr, Kajal Gupta und 3 weitere

Clinical Pharmacokinetics · 28.10.2026

DOI: 10.1007/s40262-026-01707-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 28.10.2026. Verfasst von Abdelrahman Saqr und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE…. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives The gut microbiome contributes to interindividual variability in drug pharmacokinetics; however, its role in guiding dose adjustments remains unclear. Mycophenolic acid (MPA), the active metabolite of the immunosuppressant mycophenolate mofetil (MMF), exhibits high pharmacokinetic variability, potentially linked to microbial activity. This study aimed to characterize the gut microbiome effect on MPA pharmacokinetics and determine if these effects necessitate dose modifications.

Methods

In 84 kidney transplant recipients, plasma and urine concentration-time profiles for MPA and its glucuronide metabolites were characterized using population pharmacokinetic modeling in NONMEM^®. Stool samples were collected within 2 days of pharmacokinetic sampling for microbiome shotgun metagenomic sequencing. Machine learning was used to identify microbial species associated with pharmacokinetic variability. The impact of these species and clinical covariates was evaluated using full fixed-effect modeling. Simulations were conducted to assess the effect of microbial relative abundance on MPA therapeutic target attainment across various MMF doses.

Results

Five bacteria were associated with the magnitude or duration of enterohepatic circulation (EHC). High relative abundance of Eubacterium callanderi increased EHC and MPA exposure by 29–63%, requiring a 17% lower MMF dose. Conversely, high Faecalibacterium SGB15315 abundance reduced EHC and MPA exposure by 13–26%, requiring a 50–75% higher dose. While Gemmiger formicilis and Eisenbergiella tayi prolonged EHC by >100% and Anaerostipes caccae decreased it by 30%, these taxa did not clinically impact therapeutic target attainment.

Conclusion

We identified several stool microbial species affecting MPA pharmacokinetics. Specifically, Eubacterium callanderi and Faecalibacterium SGB15315 may identify patients who require additional therapeutic drug monitoring or possible dose modifications to reach target concentrations. Clinical Trial Registration Clinicaltrials.gov, NCT04953715.

Autor:innen und Institutionen

  • Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, 7-151 Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, MN, 55455, USA.
  • Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA.
  • Department of Nephrology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
  • Department of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
  • Department of Food Science and Nutrition, University of Minnesota, St. Paul, MN, 55108, USA.
  • Division of Biostatistics and Health Data Science, School of Public Health, University of Minnesota, Minneapolis, MN, 55455, USA.

Förderung

  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Saqr, A., Mohamed, M. E., Staley, C., Onyeaghala, G., Vo, D., Remmel, R. P., Teigen, L., Guan, W., Oetting, W. S., El-Rifai, R., Dorr, C. R., Gupta, K., Matas, A. J., Israni, A. K., & Jacobson, P. A. (2026). Microbiome-Mediated Pharmacokinetics and Informed Dosing of Mycophenolate in Kidney Transplantation. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01707-4

Vancouver

Saqr A, Mohamed ME, Staley C, Onyeaghala G, Vo D, Remmel RP, et al. Microbiome-Mediated Pharmacokinetics and Informed Dosing of Mycophenolate in Kidney Transplantation. Clinical Pharmacokinetics. 2026. doi:10.1007/s40262-026-01707-4

BibTeX
@article{Saqr2026,
  author = {Saqr, Abdelrahman and Mohamed, Moataz E and Staley, Christopher and Onyeaghala, Guillaume and Vo, Duy and Remmel, Rory P and Teigen, Levi and Guan, Weihua and Oetting, William S and El-Rifai, Rasha and Dorr, Casey R and Gupta, Kajal and Matas, Arthur J and Israni, Ajay K and Jacobson, Pamala A},
  title = {Microbiome-Mediated Pharmacokinetics and Informed Dosing of Mycophenolate in Kidney Transplantation},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  doi = {10.1007/s40262-026-01707-4}
}
Kostenlos starten →